Stocksigma LogoStocksigma Logo

Alivus Life Sciences Reports Robust Q2 FY27 Operating Performance and Margin Expansion

Alivus Life Sciences reported Q2 FY27 revenue from operations of ₹6,820 Mn, rising 16.0% YoY and 6.5% QoQ, driven by a 20.8% YoY surge in non-GPL revenue

Alivus Life Sciences Reports Robust Q2 FY27 Operating Performance and Margin Expansion

Alivus Life Sciences Ltd · Investor Presentation · 30 Oct 2026, 1:05 am

Alivus Life Sciences Reports Robust Q2 FY27 Operating Performance and Margin Expansion Alivus Life Sciences reported Q2 FY27 revenue from operations of ₹6,820 Mn, rising 16.0% YoY and 6.5% QoQ, driven by a 20.8% YoY surge in non-GPL revenue to ₹5,369 Mn (79% of total). EBITDA surged 47.0% YoY to ₹2,851 Mn, with EBITDA margin expanding 880 bps YoY to 41.8% on operational efficiencies and favorable mix. PAT rose 51.3% YoY to ₹1,968 Mn. Strong free cash flow of ₹2,702 Mn lifted cash balances to ₹10,116 Mn as of 30th Sep'26. Total reactor capacity is projected to expand from 1,424 KL to 2,150 KL by FY27E.

Original exchange filing (PDF)

More announcements from Alivus Life Sciences Ltd

All Alivus Life Sciences Ltd announcements